Argos data shows disease eradication potential, says JMP Securities JMP Securities believes that immunological data from patients on Argos' AGS-004 indicates that the drug can affect latent reservoirs of HIV virus. The firm views this as a key step in virus eradication, and it thinks the data suggest the drug can be effectively combined with PD-1/PDL-1 inhibitors in HIV and oncology. It reiterates an Outperform rating on the stock.
Argos Therapeutics hires Joan Winterbottom as Chief Human Resources Officer Argos Therapeutics (ARGS) announced that Joan Winterbottom will join the company as chief human resources officer. Winterbottom most recently served as senior vice president of human resources at Amicus Therapeutics (FOLD).